Fresenius Kabi is offering Rocuronium Bromide injection with advanced RFID-enabled labels.
The product is the generic of Zemuron.
Rocuronium Bromide injection is part of Fresenius Kabi's +RFID portfolio of smart-labeled medications, designed to help enhance patient safety and support a more-efficient medication inventory process. This will mark the first +RFID product compatible with Bluesight’s KitCheck product, a kit and tray solution for American hospitals allowing +RFID products to be used across all major RFID kit and tray vendors.
The company said that using RFID technology with pharmaceutical products supports a safe, more efficient medication inventory process that eliminates manual product tagging and data entry and may help improve patient safety by reducing medical errors.
[Read more: Fresenius Kabi intros generic Tepadina]
“We’re happy to add Fresenius Kabi to our growing community of partners committed to qualifying and testing RFID products to ensure customers will be able to use them, and we are excited for the portfolio of compatible RFID products to grow. Fresenius Kabi’s use of the registry will provide hospitals the ability to instantly identify recalls and use +RFID products across the hospital system,” said Kevin MacDonald, CEO of Bluesight.
Fresenius Kabi Rocuronium Bromide injection +RFID is available in a 50 mg per 5 ml multiple dose vial. Utilizing RAIN RFID technology, the smart-labeled medication, following GS1’s open global data, has attained ARC certification by Auburn University’s RFID lab.
[Read more: Fresenius Kabi intros generic Foscavir]
"Fresenius Kabi is committed to answering our customers’ call and to support them in their search for improved methods of medication management,” said John Ducker, president and CEO of Fresenius Kabi USA. "Interoperability of our +RFID medications is critical to reducing pain points in the American hospital system.”